Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Features of C-reactive protein in COVID-19 patients within various period: a cohort study

Guoxin Huang, Gaojing Qu, Hui Yu, Meiling Zhang, Xiaoming Song, Lei Chen, Haoming Zhu, Yunfu Wang, Bin Pei
doi: https://doi.org/10.1101/2020.10.26.20219360
Guoxin Huang
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaojing Qu
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Yu
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meiling Zhang
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoming Song
2Department of Equipment Division, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Chen
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haoming Zhu
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunfu Wang
3Department of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000,China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: binpei@hbmu.edu.cn wangyun@hbmu.edu.cn
Bin Pei
1Center of Evidence-based Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: binpei@hbmu.edu.cn wangyun@hbmu.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Coronavirus disease 2019 (COVID-19) has been declared as a threat to the global. Due to the lack of efficient treatments, indicators were urgently needed during the evolvement of disease to analyze the illness and prognosis and prevent the aggravation of COVID-19.

METHODS All laboratory confirmed COVID-19 patients hospitalized in Xiangyang No.1 People’s Hospital were included. Patients’ general information, clinical type, CRP value and outcome were collected. CRP values of all patients during disease course from different initial time were analyzed.

RESULTS The 131 enrolled patients were 50.13±17.13 years old. All cases underwent 724 tests of CRP since symptom onset, 53.18% of the test results were abnormal and the median value was 9.52(2.63-34.10) mg/L. The first median value on the day 8 from exposure onset was 39.08(11.92-47.89) mg/L then fluctuated around it until the day 28. The CRP median increased from 15.93 mg/L to 41.44 mg/L and then decreased to 18.26 mg/L before transformation of severe type, and then increased to 62.25 mg/L on the transforming date. Conversely, the CRP median increased from 56.17 mg/L 102.75 mg/L before transformation of critical type but decreased to 68.68 mg/L on the transforming date. The changes of CRP median over time before death ranged from 77.77 mg/L to 133.52 mg/L.

CONCLUSIONS CRP increased before symptom onset and substantially increased during the early-to-mid stage (especially early stage), which was different from other virus-infected diseases. The changes of CRP before the transformation of clinical type was inconsistent with the aggravating of illness. And the CRP maintained over 100.00 mg/L prompted poor prognosis.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000031088

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was unanimously approved by Ethics Committee of Xiangyang NO.1 people's hospital on February 12, 2020.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Anyone who wants to obtain the original data of this study with reasonable purposes can contact the correspondent author via email.

  • Abbreviations

    COVID-19
    Coronavirus Disease 2019
    CRP
    C-reactive Protein
    WBC
    White Blood Cell
    LYMPH
    Lymphocyte
    ULN
    Upper Limit of Normal
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted October 27, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Features of C-reactive protein in COVID-19 patients within various period: a cohort study
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Features of C-reactive protein in COVID-19 patients within various period: a cohort study
    Guoxin Huang, Gaojing Qu, Hui Yu, Meiling Zhang, Xiaoming Song, Lei Chen, Haoming Zhu, Yunfu Wang, Bin Pei
    medRxiv 2020.10.26.20219360; doi: https://doi.org/10.1101/2020.10.26.20219360
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Features of C-reactive protein in COVID-19 patients within various period: a cohort study
    Guoxin Huang, Gaojing Qu, Hui Yu, Meiling Zhang, Xiaoming Song, Lei Chen, Haoming Zhu, Yunfu Wang, Bin Pei
    medRxiv 2020.10.26.20219360; doi: https://doi.org/10.1101/2020.10.26.20219360

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (161)
    • Allergy and Immunology (416)
    • Anesthesia (91)
    • Cardiovascular Medicine (860)
    • Dentistry and Oral Medicine (159)
    • Dermatology (97)
    • Emergency Medicine (250)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
    • Epidemiology (8562)
    • Forensic Medicine (4)
    • Gastroenterology (384)
    • Genetic and Genomic Medicine (1753)
    • Geriatric Medicine (167)
    • Health Economics (373)
    • Health Informatics (1244)
    • Health Policy (621)
    • Health Systems and Quality Improvement (468)
    • Hematology (196)
    • HIV/AIDS (374)
    • Infectious Diseases (except HIV/AIDS) (10303)
    • Intensive Care and Critical Care Medicine (553)
    • Medical Education (192)
    • Medical Ethics (51)
    • Nephrology (212)
    • Neurology (1678)
    • Nursing (97)
    • Nutrition (251)
    • Obstetrics and Gynecology (326)
    • Occupational and Environmental Health (451)
    • Oncology (929)
    • Ophthalmology (263)
    • Orthopedics (102)
    • Otolaryngology (172)
    • Pain Medicine (114)
    • Palliative Medicine (40)
    • Pathology (253)
    • Pediatrics (536)
    • Pharmacology and Therapeutics (253)
    • Primary Care Research (208)
    • Psychiatry and Clinical Psychology (1770)
    • Public and Global Health (3841)
    • Radiology and Imaging (624)
    • Rehabilitation Medicine and Physical Therapy (320)
    • Respiratory Medicine (520)
    • Rheumatology (208)
    • Sexual and Reproductive Health (168)
    • Sports Medicine (158)
    • Surgery (190)
    • Toxicology (36)
    • Transplantation (101)
    • Urology (76)